Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Pharma & Biotech

Agenus BOTBAL survival data challenges expectations in MSS metastatic colorectal cancer

Explore how Agenus BOTBAL achieved 33% three-year survival in refractory MSS colorectal cancer and what Phase 3 must prove next.

Read More
Pharma & Biotech

Alzheon builds oral Alzheimer’s case around brain microstructure and lower ARIA risk

Explore how Alzheon’s new valiltramiprosate brain and safety data could reshape oral Alzheimer’s treatment after a Phase 3 setback.

Read More
Representative image: A clinical laboratory workflow for Signatera molecular residual disease testing, which may help identify chemotherapy survival benefit after colorectal liver metastasis surgery.
Pharma & Biotech

Why Natera’s latest Signatera study matters for resected metastatic colorectal cancer

Discover how Natera’s Signatera MRD test may sharpen chemotherapy decisions after colorectal liver surgery and what remains unproven.

Read More
Representative image: Aurinia Pharmaceuticals is evaluating Lupkynis in combination with belimumab, obinutuzumab or anifrolumab in the PRESERVE lupus nephritis study.
Pharma & Biotech

Why Aurinia’s new Lupkynis trial could change the lupus nephritis treatment sequence

Discover how Aurinia’s PRESERVE study could reshape lupus nephritis care by combining Lupkynis with three major biologic therapies.

Read More
Representative image: Retinal imaging analysis highlights the clinical delivery and manufacturing challenges facing Lineage Cell Therapeutics as OpRegen advances in geographic atrophy and OPC1 progresses in spinal cord injury.
Pharma & Biotech

Can Lineage turn early retinal repair signals into a credible late-stage OpRegen pathway?

Discover why Lineage Cell Therapeutics’ OpRegen and OPC1 programmes now face critical delivery, trial design and manufacturing tests.

Read More
Pharma & Biotech

PharmaEssentia wins Health Canada approval for BESREMi in polycythemia vera

Read how Health Canada’s BESREMi approval could reshape polycythemia vera treatment, reimbursement and PharmaEssentia’s Canadian strategy.

Read More
Incyte’s acquisition of Vega Therapeutics adds the Phase 3 monoclonal antibody VGA039 to its hematology pipeline, strengthening its strategy in von Willebrand disease treatment. Representative image.
Pharma & Biotech

Incyte closes $2bn Vega Therapeutics deal as VGA039 reshapes VWD strategy

Incyte has acquired Vega Therapeutics and Phase 3 VWD antibody VGA039. Explore the clinical promise, deal strategy and risks ahead.

Read More
Representative image: Biopharmaceutical manufacturing facility illustrating Orion Corporation and Shilpa Medicare’s partnership to develop and supply a nivolumab biosimilar for the European oncology market.
Pharma & Biotech

Shilpa Medicare secures Orion for European nivolumab biosimilar commercialization and supply

Discover how Orion and Shilpa Medicare’s nivolumab biosimilar deal could reshape European oncology access, pricing and hospital procurement.

Read More
Pharma & Biotech

MaaT Pharma AGM strengthens funding authority as MaaT013 faces September regulatory test

MaaT Pharma shareholders have preserved the biotechnology firm’s ability to raise capital as MaaT013 enters a decisive regulatory re-examination and its operating cash runway narrows.

Read More
Representative image: Tepkinly’s European approval expands bispecific antibody treatment options for adults with relapsed or refractory follicular lymphoma, potentially reshaping second-line lymphoma care.
Pharma & Biotech

Genmab and AbbVie secure EU approval for Tepkinly in relapsed follicular lymphoma

Discover how Tepkinly’s EU approval could reshape second-line follicular lymphoma treatment and the safety and access questions still ahead.

Read More